Azvudine therapy of common COVID‐19 in hemodialysis patients
Open Access
- 31 July 2023
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (8) , e29007
Abstract
There is no antiviral study on hemodialysis patients infected with coronavirus disease 2019 (COVID‐19), especially on the application of 2′‐deoxy‐2′‐β ‐fluoro‐4′‐azidocytidine (Azvudine, FNC) antiviral therapy. We conducted a multicenter observational study involving 1008 hemodialysis patients. After matching for age, sex, and other factors, 182 patients in the basic treatment group and 182 in the FNC group were included. The negative nucleic acid conversion rate of the FNC group was significantly higher than that of the basic treatment group, and viral loads, interleukin‐6, and C‐reactive protein were significantly lower than those of the basic treatment group (p < 0.05). There were no significant differences in liver function, renal function, or the number of adverse events between the two groups (p > 0.05). In conclusion, our study has provided novel evidence suggesting that the FNC scheme may be safe and effective compared to the basic treatment of hemodialysis patients with common COVID‐19.Keywords
This publication has 26 references indexed in Scilit:
- COVID-19 vaccination in patients receiving dialysisNature Reviews Nephrology, 2021
- Myocarditis With COVID-19 mRNA VaccinesCirculation, 2021
- Risk prediction of COVID-19 incidence and mortality in a large multi-national hemodialysis cohort: implications for management of the pandemic in outpatient hemodialysis settingsClinical Kidney Journal, 2021
- COVID-19 and maintenance hemodialysis: a systematic scoping review of practice guidelinesBMC Nephrology, 2020
- Effective Prevention and Management of COVID-19 in Outpatient Hemodialysis PatientsThe American Journal of Managed Care, 2020
- Azvudine (FNC): a promising clinical candidate for COVID-19 treatmentSignal Transduction and Targeted Therapy, 2020
- AKI in Hospitalized Patients with COVID-19Journal of the American Society of Nephrology, 2020
- A Randomized, Open‐Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID‐19, a Pilot StudyAdvanced Science, 2020
- A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infectionKidney International, 2020
- The Pyrimidine Analog FNC Potently Inhibits the Replication of Multiple EnterovirusesJournal of Virology, 2020